论文部分内容阅读
目的研究拉米夫定治疗失代偿期乙肝肝硬化的疗效及不良反应。方法 76例失代偿期乙肝肝硬化患者,抽签随机分为对照组和观察组,各38例。两组均给予常规护肝、调节免疫和抗感染等常规治疗,观察组在常规治疗基础上加用拉米夫定治疗,比较两组持续治疗1年后的疗效。结果两组治疗后较治疗前肝功能丙氨酸转氨酶(ALT)、门冬氨酸转氨酶(AST)、总胆红素(TBIL)指标均显著下降(P<0.05);治疗后观察组较对照组下降更为显著(P<0.05);血清标志物乙肝e抗原(Hbe Ag)转阴率较对照组明显较高(P<0.05);对照组、观察组不良反应发生率分别为10.53%、7.89%,比较差异无统计学意义(P>0.05)。结论拉米夫定能有效降低失代偿期乙肝肝硬化患者的ALT、AST、TBIL等指标的表达水平,抑制乙型肝炎病毒(HBV)的复制和改善肝功能,且在常规治疗基础上加用拉夫米定治疗未增加其他不良反应症状,患者耐受性较好,可作为临床较为安全有效的治疗药物。
Objective To study the efficacy and adverse reactions of lamivudine in the treatment of decompensated hepatitis B cirrhosis. Methods Seventy-six patients with decompensated hepatitis B cirrhosis were randomized into control group and observation group with 38 patients in each group. Both groups were given conventional liver protection, immunization and anti-infection and other conventional treatment, the observation group on the basis of conventional therapy plus lamivudine treatment, the two groups were compared 1 year after treatment. Results After treatment, the indexes of ALT, AST and TBIL were significantly decreased in both groups after treatment (P <0.05). Compared with the control group (P <0.05). The negative rate of serum HbAg was significantly higher than that of the control group (P <0.05). The incidences of adverse reactions in the control group and the observation group were 10.53% 7.89%, the difference was not statistically significant (P> 0.05). Conclusion Lamivudine can effectively reduce the expression of ALT, AST, TBIL and other indicators in patients with decompensated hepatitis B cirrhosis, inhibit the replication of hepatitis B virus (HBV) and improve the liver function, and on the basis of routine treatment With lamivudine treatment did not increase the other symptoms of adverse reactions, patients with better tolerance, can be used as a more safe and effective clinical treatment of drugs.